Guggenheim Capital’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $726K | Sell |
51,860
-4,152
| -7% | -$58.1K | 0.01% | 1009 |
|
|
2025
Q1 | $762K | Buy |
56,012
+7,881
| +16% | +$107K | 0.01% | 998 |
|
|
2024
Q4 | $981K | Buy |
48,131
+27,518
| +133% | +$561K | 0.01% | 931 |
|
|
2024
Q3 | $600K | Buy |
20,613
+694
| +3% | +$20.2K | ﹤0.01% | 1333 |
|
|
2024
Q2 | $463K | Buy |
19,919
+200
| +1% | +$4.64K | ﹤0.01% | 1466 |
|
|
2024
Q1 | $405K | Buy |
19,719
+2,323
| +13% | +$47.7K | ﹤0.01% | 1556 |
|
|
2023
Q4 | $373K | Sell |
17,396
-39,974
| -70% | -$858K | ﹤0.01% | 1575 |
|
|
2023
Q3 | $1.18M | Buy |
57,370
+3,584
| +7% | +$73.9K | 0.01% | 1026 |
|
|
2023
Q2 | $1.59M | Sell |
53,786
-2,458
| -4% | -$72.5K | 0.01% | 952 |
|
|
2023
Q1 | $1.3M | Sell |
56,244
-8,447
| -13% | -$195K | 0.01% | 1045 |
|
|
2022
Q4 | $1.8M | Buy |
64,691
+14,256
| +28% | +$396K | 0.02% | 892 |
|
|
2022
Q3 | $1.55M | Sell |
50,435
-10,572
| -17% | -$324K | 0.01% | 946 |
|
|
2022
Q2 | $1.8M | Buy |
61,007
+6,580
| +12% | +$194K | 0.01% | 934 |
|
|
2022
Q1 | $1.75M | Buy |
54,427
+7,445
| +16% | +$240K | 0.01% | 1084 |
|
|
2021
Q4 | $2.1M | Buy |
+46,982
| New | +$2.1M | 0.01% | 1033 |
|